Prolonged progestin treatment induces the promoter of CDK inhibitor p21Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells

Experimental Cell Research

Volumn 284, Issue 2, 2003, Pages 262-271

  Kester, Henri A ^a,b   Sonneveld, Edwin ^a   Van Der Saag, Paul T ^a   Van Der Burg, Bart ^a  

^a HUBRECHT INSTITUTE   (Netherlands)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

ECC1; Endometrial cancer; Mammary carcinoma; p21Cip1,Waf1; p53; Progestin; T47D

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; GESTAGEN; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; GENE MUTATION; HUMAN; HUMAN CELL; LONG TERM CARE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN INDUCTION; UPREGULATION;

EID: 0037376546     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00017-4     Document Type: Article

References (44)

1. Greenspan F.S., Baxter J.D. Basic and Clinical Endocrinology. 4th ed. 1994;Appleton & Lange, East Norwalk, CO.
2. Clarke C.L., Sutherland R.L. Progestin regulation of cellular proliferation. Endocrine Rev. 11:1990;266-301.
3. Clarke C.L., Sutherland R.L. Progestin regulation of cellular proliferation An update . Endocrine Rev. 14:1993;132-135.
4. Horwitz K.B., Freidenberg G.R. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins Implications for endocrine therapies . Cancer Res. 45:1985;167-173.
5. Sarup J.C., Rao K.V., Fox C.F. Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor. Cancer Res. 48:1988;5071-5078.
6. Sutherland R.L., Hall R.E., Pang G.Y., Musgrove E.A., Clarke C.L. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48:1988;5084-5091.
7. Musgrove E.A., Lee C.S.L., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11:1991;5032-5043.
8. Kester H.A., Van der Leede B.M., Van der Saag P.T., Van der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J. Biol. Chem. 272:1997;16637-16643.
9. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
10. Kalkhoven E., Wissink S., Van der Saag P.T., Van der Burg B. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. J. Biol. Chem. 271:1996;6217-6224.
11. Göttlicher M., Heck S., Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. 76:1998;480-489.
12. Groshong S.D., Owen G.I., Grimison B., Schauer I.E., Todd M.C., Langan T.A., Sclafani R.A., Langè C.A., Horwitz K.B. Biphasic regulation of breast cancer cell growth by progesterone Role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1) . Mol. Endocrinol. 11:1997;1593-1607.
13. Musgrove E.A., Swarbrick A., Lee C.S.L., Cornish A.L., Sutherland R.L. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1998;1812-1825.
14. Swarbrick A., Lee C.S., Sutherland R.L., Musgrove E.A. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20:2000;2581-2591.
15. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
16. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
17. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
18. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
19. El-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., Hamilton S.R., et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:1995;2910-2919.
20. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell Res. 246:1999;280-289.
21. Owen G.I., Richer J.K., Tung L., Takimoto G., Horwitz K.B. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273:1998;10696-10701.
22. Datto M.B., Yu Y., Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270:1995;28623-28628.
23. Joore J., Fasciana C., Speksnijder J.E., Kruijer W., Destree O.H., van den Eijnden-van Raaij A.J., de Laat S.W., Zivkovic D. Regulation of the zebrafish goosecoid promoter by mesoderm inducing factors and Xwnt1. Mech. Dev. 55:1996;3-18.
24. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1:1992;45-49.
25. Hurd C., Khattree N., Alban P., Nag K., Jhanwar S.C., Dinda S., Moudgil V.K. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J. Biol. Chem. 270:1995;28507-28510.
26. Blagosklonny M.V. p53 from complexity to simplicity Mutant p53 stabilization, gain-of-function, and dominant-negative effect . FASEB J. 14:2000;1901-1907.
27. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
28. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
29. Lambert P.F., Kashanchi F., Radonovich M.E., Shiekhattar R., Brady J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273:1998;33048-33053.
30. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
31. Johnson-Pais T., Degnin C., Thayer M.J. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc. Natl. Acad. Sci. USA. 98:2001;2211-2216.
32. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer Mutation and nuclear exclusion . Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
33. Moll U.M., LaQuaglia M., Benard J., Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4407-4411.
34. Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J.J., Lee A.K.C. Cytoplasmic accumulation of p53 protein An independent prognostic indicator in colorectal adenocarcinomas . J. Natl. Cancer Inst. 86:1994;681-687.
35. Weiss J., Heine M., Korner B., Pilch H., Jung E.G. Expression of p53 protein in malignant melanoma Clinicopathological and prognostic implications . Br. J. Dermatol. 133:1995;23-31.
36. Kuperwasser C., Pinkas J., Hurlbut G.D., Naber S.P., Jerry D.J. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res. 60:2000;2723-2729.
37. Sivaraman L., Conneely O.M., Medina D., O'Malley B.W. Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. Proc. Natl. Acad. Sci. USA. 98:2001;12379-12384.
38. Amundson S.A., Myers T.G., Fornace A.J. Jr. Roles for p53 in growth arrest and apoptosis Putting on the brakes after genotoxic stress . Oncogene. 17:1998;3287-3299.
39. Yamamoto M., Yoshida M., Ono K., Fujita T., Ohtani-Fujita N., Sakai T., Nikaido T. Effect of tumor suppressors on cell cycle-regulatory genes RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression . Exp. Cell Res. 210:1994;94-101.
40. Desdouets C., Ory C., Matesic G., Soussi T., Brechot C., Sobczak-Thepot J. ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. FEBS Lett. 385:1996;34-38.
41. Innocente S.A., Abrahamson J.L., Cogswell J.P., Lee J.M. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. USA. 96:1999;2147-2152.
42. Kandouz M., Siromachkova M., Jacob D., Chretien Marquet B., Therwath A., Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int. J. Cancer. 68:1996;120-125.
43. Formby B., Wiley T.S. Progesterone inhibits growth and induces apoptosis in breast cancer cells Inverse effects on Bcl-2 and p53 . Ann. Clin. Lab. Sci. 28:1998;360-369.
44. Kandouz M., Lombet A., Perrot J.Y., Jacob D., Carvajal S., Kazem A., Rostene W., Therwath A., Gompel A. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J. Steroid Biochem. Mol. Biol. 69:1999;463-471.